what are the risks of taking glp 1 GLP-1 Agonists In Obesity Common GLP-1 Side Effects and
Description
Romeo S, Sentinelli F, Dash S et al (2010) Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent
The data are limited at this time, but case reports show that people taking GLP-1 meds reported increased energy, reduced pain, and reduced fatigue
But the shortage has since ended, and the pharmacies have continued to make their own versions, under laws that allow them to make drugs for specific patients
Why this letter matters beyond the walls of one pharmacy The compounding of GLP-1 receptor agonists has exploded alongside the surging demand for semaglutide and tirzepatide
10.1002/dmrr.3843 15 KochanekK
